CL2013001001A1 - Composicion farmaceutica que comprende el acido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclohexil)-acetico, tensoactivos, aglutinantes secos con propiedades desintegrantes, rellenos y desintegrantes; proceso de preparacion y uso en un trastorno asociado a dgat1. - Google Patents
Composicion farmaceutica que comprende el acido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclohexil)-acetico, tensoactivos, aglutinantes secos con propiedades desintegrantes, rellenos y desintegrantes; proceso de preparacion y uso en un trastorno asociado a dgat1.Info
- Publication number
- CL2013001001A1 CL2013001001A1 CL2013001001A CL2013001001A CL2013001001A1 CL 2013001001 A1 CL2013001001 A1 CL 2013001001A1 CL 2013001001 A CL2013001001 A CL 2013001001A CL 2013001001 A CL2013001001 A CL 2013001001A CL 2013001001 A1 CL2013001001 A1 CL 2013001001A1
- Authority
- CL
- Chile
- Prior art keywords
- pyridin
- disintegrating
- acid
- dgat1
- trifluoro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39310310P | 2010-10-14 | 2010-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013001001A1 true CL2013001001A1 (es) | 2013-10-25 |
Family
ID=44908106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013001001A CL2013001001A1 (es) | 2010-10-14 | 2013-04-12 | Composicion farmaceutica que comprende el acido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclohexil)-acetico, tensoactivos, aglutinantes secos con propiedades desintegrantes, rellenos y desintegrantes; proceso de preparacion y uso en un trastorno asociado a dgat1. |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US20130190354A1 (es) |
| EP (1) | EP2627319B1 (es) |
| JP (1) | JP6060081B2 (es) |
| KR (1) | KR20130100311A (es) |
| CN (1) | CN103179957B (es) |
| AR (1) | AR083417A1 (es) |
| AU (1) | AU2011316003B2 (es) |
| BR (1) | BR112013008757A2 (es) |
| CA (1) | CA2813781C (es) |
| CL (1) | CL2013001001A1 (es) |
| CO (1) | CO6710915A2 (es) |
| DK (1) | DK2627319T3 (es) |
| EC (1) | ECSP13012755A (es) |
| ES (1) | ES2712064T3 (es) |
| GT (1) | GT201300096A (es) |
| HU (1) | HUE043524T2 (es) |
| IL (1) | IL225434A0 (es) |
| MA (1) | MA34599B1 (es) |
| MX (1) | MX2013004162A (es) |
| NZ (1) | NZ608558A (es) |
| PE (1) | PE20140375A1 (es) |
| PL (1) | PL2627319T3 (es) |
| PT (1) | PT2627319T (es) |
| RU (1) | RU2595866C2 (es) |
| SG (1) | SG189078A1 (es) |
| SI (1) | SI2627319T1 (es) |
| TR (1) | TR201902435T4 (es) |
| WO (1) | WO2012051488A1 (es) |
| ZA (1) | ZA201302108B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR083417A1 (es) | 2010-10-14 | 2013-02-21 | Novartis Ag | Composiciones farmaceuticas que contienen un dgat1 inhibidor |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| EP2841432A1 (en) * | 2012-04-27 | 2015-03-04 | Novartis AG | Tetrahydropyran dgat1 inhibitors |
| WO2013169648A1 (en) * | 2012-05-07 | 2013-11-14 | Novartis Ag | Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| CN114099496A (zh) | 2015-03-13 | 2022-03-01 | 艾斯柏伦治疗公司 | 含etc1002和依泽替米贝的组合及治疗方法 |
| MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| EP3391881A4 (en) | 2015-11-19 | 2020-03-11 | Sinew Pharma Inc. | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING HEPATIC STEATOSIS |
| JP7085985B2 (ja) | 2016-03-04 | 2022-06-17 | 大鵬薬品工業株式会社 | 悪性腫瘍治療用製剤及び組成物 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| US20180338922A1 (en) * | 2017-05-26 | 2018-11-29 | Esperion Therapeutics, Inc. | Fixed dose formulations |
| US10632092B2 (en) | 2017-08-30 | 2020-04-28 | First Fruits Business Ministry, Llc | Composition for and method to increase serum adiponectin and reduce body fat |
| EP3765012A4 (en) | 2018-03-16 | 2021-12-15 | Anji Pharmaceuticals Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF SERIOUS CONSTIPATION |
| AU2019239404B2 (en) | 2018-03-19 | 2021-12-23 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE271863T1 (de) | 1995-11-14 | 2004-08-15 | Abbott Gmbh & Co Kg | Schilddrüsenhormone enthaltende stabilisierte arzneimittel und verfahren |
| GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| DE19816070A1 (de) * | 1998-04-09 | 1999-10-14 | Aventis Res & Tech Gmbh & Co | Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden |
| NZ532707A (en) * | 2001-12-21 | 2006-07-28 | Pfizer Prod Inc | Directly compressible formulations of azithromycin |
| EP1874317A4 (en) * | 2005-04-19 | 2011-10-26 | Bayer Healthcare Llc | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES IN THE TREATMENT OF OBESITY |
| KR101219042B1 (ko) * | 2005-12-06 | 2013-01-07 | 삼성디스플레이 주식회사 | 반투과형 액정 표시 장치 |
| WO2007078726A2 (en) | 2005-12-16 | 2007-07-12 | Merck & Co., Inc. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
| AR059739A1 (es) | 2006-03-06 | 2008-04-23 | Wyeth Corp | Formulaciones y procesos para tabletas |
| US20070224258A1 (en) | 2006-03-22 | 2007-09-27 | Bunick Frank J | Dosage forms having a randomized coating |
| PL2402319T3 (pl) * | 2006-03-31 | 2018-02-28 | Novartis Ag | Inhibitory DGAT |
| EP2117526B1 (en) | 2006-11-29 | 2013-04-03 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
| US20080145425A1 (en) * | 2006-12-15 | 2008-06-19 | Pliva Research & Development Limited | Pharmaceutical composition of zolpidem |
| US8242139B2 (en) | 2007-04-30 | 2012-08-14 | Abbott Laboratories | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme |
| US8283331B2 (en) * | 2007-10-09 | 2012-10-09 | Children's Medical Center Corporation | Methods to regulate miRNA processing by targeting Lin-28 |
| DK3222277T3 (da) * | 2009-03-31 | 2020-05-11 | Ligand Pharm Inc | Biphenylsulfonamidendothelin- og angiotensin II-receptorantagonist til behandling af glomerulosklerose og IgA-induceret nefropati |
| BR112012024618A2 (pt) * | 2010-03-30 | 2019-09-24 | Novartis Ag | usos de inibidores de dgat1 |
| AR083417A1 (es) | 2010-10-14 | 2013-02-21 | Novartis Ag | Composiciones farmaceuticas que contienen un dgat1 inhibidor |
-
2011
- 2011-10-13 AR ARP110103797A patent/AR083417A1/es unknown
- 2011-10-14 RU RU2013121795/15A patent/RU2595866C2/ru active
- 2011-10-14 PL PL11779278T patent/PL2627319T3/pl unknown
- 2011-10-14 CA CA2813781A patent/CA2813781C/en active Active
- 2011-10-14 WO PCT/US2011/056275 patent/WO2012051488A1/en active Application Filing
- 2011-10-14 TR TR2019/02435T patent/TR201902435T4/tr unknown
- 2011-10-14 MX MX2013004162A patent/MX2013004162A/es not_active Application Discontinuation
- 2011-10-14 MA MA35806A patent/MA34599B1/fr unknown
- 2011-10-14 US US13/825,919 patent/US20130190354A1/en not_active Abandoned
- 2011-10-14 NZ NZ608558A patent/NZ608558A/en not_active IP Right Cessation
- 2011-10-14 DK DK11779278.8T patent/DK2627319T3/en active
- 2011-10-14 PE PE2013000837A patent/PE20140375A1/es not_active Application Discontinuation
- 2011-10-14 JP JP2013534025A patent/JP6060081B2/ja active Active
- 2011-10-14 PT PT11779278T patent/PT2627319T/pt unknown
- 2011-10-14 EP EP11779278.8A patent/EP2627319B1/en active Active
- 2011-10-14 SG SG2013021944A patent/SG189078A1/en unknown
- 2011-10-14 KR KR1020137009333A patent/KR20130100311A/ko not_active Application Discontinuation
- 2011-10-14 ES ES11779278T patent/ES2712064T3/es active Active
- 2011-10-14 BR BR112013008757-9A patent/BR112013008757A2/pt not_active IP Right Cessation
- 2011-10-14 SI SI201131677T patent/SI2627319T1/sl unknown
- 2011-10-14 AU AU2011316003A patent/AU2011316003B2/en not_active Ceased
- 2011-10-14 HU HUE11779278A patent/HUE043524T2/hu unknown
- 2011-10-14 CN CN201180049179.4A patent/CN103179957B/zh active Active
-
2013
- 2013-03-20 ZA ZA2013/02108A patent/ZA201302108B/en unknown
- 2013-03-21 IL IL225434A patent/IL225434A0/en unknown
- 2013-04-11 CO CO13094273A patent/CO6710915A2/es not_active Application Discontinuation
- 2013-04-11 GT GT201300096A patent/GT201300096A/es unknown
- 2013-04-12 CL CL2013001001A patent/CL2013001001A1/es unknown
- 2013-04-12 EC ECSP13012755 patent/ECSP13012755A/es unknown
-
2015
- 2015-07-22 US US14/805,919 patent/US20150320687A1/en not_active Abandoned
-
2016
- 2016-09-12 US US15/262,056 patent/US20160374947A1/en not_active Abandoned
-
2018
- 2018-05-01 US US15/968,104 patent/US10646446B2/en active Active
-
2020
- 2020-03-31 US US16/835,921 patent/US11304907B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013001001A1 (es) | Composicion farmaceutica que comprende el acido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclohexil)-acetico, tensoactivos, aglutinantes secos con propiedades desintegrantes, rellenos y desintegrantes; proceso de preparacion y uso en un trastorno asociado a dgat1. | |
| BR112014028755A2 (pt) | composição de argamassa de poliuretano, processo para preparação da composição de argamassa de poliuretano, e, uso de uma composição de argamassa de poliuretano. | |
| CL2007001972A1 (es) | Ester isopropilico del acido 4-[6-(6-metanosulfonil-2-metilpiridin-3-ilamino)-5-metilpirimidin-4-iloxi]piperidin-1-carboxilico, moduladores del metabolismo; composicion farmaceutica; y su uso para tratar trastornos metabolicos. | |
| CL2013000052A1 (es) | Proceso para la produccion de lignina precipitada a partir de licor negro; lignina precipitada; solucion que comprende a dicha lignina precipitada; y uso de dicha lignina precipitada. | |
| BR112012015033A2 (pt) | composição não fermentada que tem a capacidade de aumentar a formação de ácido burítico no cólon, composição não fermentada seca que tem a capacidade de aumentar a formação de ácido burítico no cólon e uso de composição não fermentada | |
| BRPI1006449A2 (pt) | composição de poliol estável em armazenamento, formulação para o preparo de uma espuma de poliisocianurato e método para o preparo de uma espuma de poliisocianurato | |
| PL2601252T3 (pl) | Nanokompozyt polimerowy zawierający kwas polimlekowy wzmocniony zmodyfikowanym filokrzemianem | |
| CL2013000929A1 (es) | Forma cristalina c de la sal sodica del acido (4-(4-(5-(6-trifluoro metil piridin-3-il-amino) piridin-2-il-) fenil)-ciclohexil)-acetico; proceso de preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento de un trastorno asociado con la actividad del dagt. | |
| WO2014186376A3 (en) | Multi-use building block and methods for the use | |
| BR112013015005A2 (pt) | corpo moldado contendo lignocelulose em multicamadas, processo para sua produção, e, uso do corpo moldado | |
| BR112012032978A2 (pt) | composição compreendendo uma formulação de revestimento em pó curável sólida, uso de pelo menos uma resina de dióxido de divinilareno, revestimento curado, artigo e processo para preparar uma composição | |
| KR101169998B9 (ko) | 분말수지 및 화이버를 사용한 라텍스 개질 콘크리트 제조용 시멘트 조성물 | |
| HRP20160779T1 (hr) | Lignocelulozni materijali s lignoceluloznim vlaknima u vanjskim slojevima i ekspandiranim plastičnim česticama u jezgri, kao i postupci i njihova primjena | |
| CL2013000089A1 (es) | Tableta de desintegracion rapida en la cavidad oral que contiene particulas nucleares con acido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazolcarboxilico y que estan recubiertas con dos capas. | |
| MX2012007630A (es) | Incremento de volumen para material colocado por aire. | |
| EP2557151A4 (en) | S-ADENOSYL-L-METHIONINE-CONTAINING DRYING COMPOSITION WITH EXCELLENT STORAGE STABILITY AND METHOD OF MANUFACTURING THEREOF | |
| CL2013000902A1 (es) | Composición en forma de gránulos peletizados a base de esporas y arcillas minerales ; proceso para obtener dicha composición. | |
| CL2015000195A1 (es) | Composicion sol-gel sensible al calor capaz de ser inyectada, constituida de una solucion acuosa de por lo menos un poliuretano anfifílico, adaptado para ser sintetizado a traves de una mezcla que comprende al menos uno o dos macrodioles con al menos un bloque peg, y un diisociabato. | |
| ZA201309038B (en) | New process for the synthesis of 3-(2-bromo-4,5-dimethoxyphenyl)propanenitrile, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | |
| GB201405031D0 (en) | Storage stable premixed hydraulic cement compositions, cements, methods, and articles | |
| Chumaevskii et al. | Mechanical strength characterization of three-component composite structural components | |
| HK1191318A1 (zh) | 合成 -溴- -二甲氧基苯基 丙腈的新方法以及在合成伊伐布雷定和其與藥學上可接受的酸的加成鹽中的應用 | |
| Köhler et al. | Timber Structures | |
| Del Gado | Heterogeneous Glasses and Sustainable Cement | |
| WO2013158823A3 (en) | Chemical oxygen generator |